First-in-class small molecule potentiators of cancer virotherapy

Area of Science:

• Oncolytic virotherapy
• Cancer therapeutics
• Medicinal chemistry

Background:

• Engineered viral strains, including oncolytic viruses (OVs), show promise for selective cancer cell destruction and revolutionizing cancer therapy.
• OV therapy is generally safe and well-tolerated in humans, with the ability to infect a broad range of cancers.
• Variable response rates in clinical studies are attributed to tumor heterogeneity, necessitating strategies to improve viral replication efficacy.

Purpose of the Study:

• To develop a new class of small molecules for selectively enhancing OV replication in cancer tissue.
• To identify compounds that improve the efficacy of OV therapy and gene therapy vectors.
• To address the limitations posed by tumor heterogeneity in OV therapeutics.

Main Methods:

• Medicinal chemistry studies were conducted to identify and optimize small molecule compounds.
• In vitro assays were used to measure the enhancement of OV growth by lead compounds.
• Ex vivo and in vivo studies assessed the selectivity of compounds for cancer cells over normal tissue.

Main Results:

• Lead compounds demonstrated up to a 2000-fold increase in OV growth in vitro.
• Compounds exhibited remarkable selectivity for cancer cells compared to normal tissue, both ex vivo and in vivo.
• The developed small molecules showed enhanced stability, reduced electrophilicity, and were well-tolerated in animal models.

Conclusions:

• A novel class of small molecules has been developed that selectively enhances OV replication in cancer.
• This pharmacoviral approach potentiates OV therapy, expanding its scope to include resistant tumors.
• The strategy is adaptable for enhancing other attenuated viral vectors, offering a transformative approach to cancer treatment.